Jonathan E. Rosenberg, MD, on Enfortumab Vedotin-ejfv vs Chemotherapy in Urothelial Cancer: Practical Clinical Considerations

Posted: Friday, July 8, 2022

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses the implications of phase III findings from the EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and consistent survival advantage over standard chemotherapy in patients with previously treated advanced urothelial carcinoma. Dr. Rosenberg outlines patient selection, management of side effects, and ongoing research.